Garry Lowenthal Joins PetVivo Holdings, Inc. as the Chief Financial Officer
11 mars 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, March 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
PetVivo Holdings, Inc. Commences Trading on Upstream Under PETV
05 mars 2024 08h00 HE
|
PetVivo Holdings, Inc.
PetVivo Dual Lists on Upstream's Global Securities Trading App MINNEAPOLIS, MN, March 05, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging...
Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California
29 févr. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...
PetVivo Holdings, Inc. Approved to Dual List on Upstream
27 févr. 2024 08h00 HE
|
PetVivo Holdings, Inc.
Trading to begin on March 5, 2024 under “PETV”, all shareholders to receive commemorative NFT MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW)...
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA
13 févr. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Feb. 13, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative...
PetVivo Reports Third Quarter of Fiscal 2024 Financial Results
12 févr. 2024 16h00 HE
|
PetVivo Holdings, Inc.
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the...
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
09 févr. 2024 07h00 HE
|
OKYO Pharma LTD
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
07 févr. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024
06 févr. 2024 12h37 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technology
31 janv. 2024 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...